Swaza

Swaza is revolutionizing global respiratory care with AeroHeal, the first non-invasive inhalable nanofluid designed to treat low blood oxygen levels. Addressing a $56 billion healthcare burden caused by hypoxemia, Swaza's innovative solution enhances oxygenation and removes excess carbon dioxide without the need for supplemental oxygen. Formulated from safe, non-toxic ingredients, AeroHeal is portable, stable at room temperature, and requires only simple equipment for administration. With no direct competitors and significant advantages over existing treatments like mechanical ventilation and steroids, Swaza is poised to transform respiratory care. Backed by a team of experts and significant early traction, including contracts with the US Biomedical Advanced Research and Development Authority (BARDA) and recognition by Johnson & Johnson's Blue Knight program, Swaza is ready to enter clinical trials and bring its groundbreaking technology to market. For more details, visit (https://www.swaza.life) or contact us at info@swaza.life.